Phase 1 Trial of Allogeneic Gene-Modified Tumor Cell Vaccine RCC-26/CD80/IL-2 in Patients with Metastatic Renal Cell Carcinoma-Reference-Cited by-同舟云学术

Phase 1 Trial of Allogeneic Gene-Modified Tumor Cell Vaccine RCC-26/CD80/IL-2 in Patients with Metastatic Renal Cell Carcinoma

Published:2010-03 Issue:3 Volume:21 Page:285-297
ISSN:1043-0342
Container-title:Human Gene Therapy
language:en
Short-container-title:Human Gene Therapy

Author:

Buchner Alexander¹²,Pohla Heike²³,Willimsky Gerald⁴⁵,Frankenberger Bernhard³,Frank Ronald⁶,Baur-Melnyk Andrea⁷,Siebels Michael¹,Stief Christian G.¹,Hofstetter Alfons²,Kopp Joachim⁸,Pezzutto Antonio⁸⁹,Blankenstein Thomas⁴⁵,Oberneder Ralph¹¹⁰,Schendel Dolores J.³

Affiliation:

1. Department of Urology, Ludwig Maximilian University of Munich, 81377 Munich, Germany.

2. Laboratory of Tumor Immunology, LIFE Center, Ludwig Maximilian University of Munich, 81377 Munich, Germany.

3. Institute of Molecular Immunology, Helmholtz Zentrum München, German Research Center for Environmental Health, and Clinical Cooperation Group “Immune Monitoring,” 81377 Munich, Germany.

4. Max Delbrück Center for Molecular Medicine, 13092 Berlin, Germany.

5. Institute of Immunology, Charité-University Medicine, Campus Benjamin Franklin, 12200 Berlin, Germany.

6. Department of Chemical Biology, Helmholtz Center for Infection Research, 38124 Braunschweig, Germany.

7. Department of Clinical Radiology, Ludwig Maximilian University of Munich, 81377 Munich, Germany.

8. Department of Hematology, Oncology, and Tumor Immunology, Charité-University Medicine, Campus Berlin-Buch, 13125 Berlin, Germany.

9. Department of Hematology and Oncology, Charité-University Medicine, Campus Virchow-Klinikum, 13353 Berlin, Germany.

10. Present address: Urological Clinic Dr. Castringius Munich-Planegg, 82152 Munich-Planegg, Germany.

Publisher

Mary Ann Liebert Inc

Subject

Genetics,Molecular Biology,Molecular Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/hum.2008.192

Reference54 articles.

1. Phase I Trial of a B7-1 (CD80) Gene Modified Autologous Tumor Cell Vaccine in Combination With Systemic Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma

2. Allogeneic retrovirally transduced, IL-2- and IFN-γ-secreting cancer cell vaccine in patients with hormone refractory prostate cancer—a phase I clinical trial

3. The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays

4. Identification of HLA-A2–Restricted T-Cell Epitopes Derived From the MUC1 Tumor Antigen for Broadly Applicable Vaccine Therapies

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer Vaccines;Plotkin's Vaccines;2023

2. Combining the past and present to advance immuno-radiotherapy of cancer;International Reviews of Immunology;2021-09-12

3. Immune Checkpoint Regulators: A New Era Toward Promising Cancer Therapy;Current Cancer Drug Targets;2020-07-07

4. Immunomodulatory Therapies for Renal Cell Carcinoma;Protein & Peptide Letters;2018-08-28

5. Identification of patient-specific and tumor-shared T cell receptor sequences in renal cell carcinoma patients;Oncotarget;2017-02-03